Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Pathophysiology and New Treatment of Itch
share announcement

Pathophysiology and New Treatment of Itch

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: closed (1 May 2021) | Viewed by 5529

Special Issue Editors

Prof. Dr. Hye One Kim

E-Mail Website
Guest Editor
Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University, 1 Singil-ro, Seoul 07441, Korea
Interests: pruritus; postburn pruritus; itch, atopic dermatitis; psoriasis
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Won-Sik Shim

E-Mail Website
Guest Editor
College of Pharmacy, Gachon University, Incheon, Korea
Interests: pruritus; ion channel; GPCR; calcium imaging; sensory neuron

Special Issue Information

Dear Colleagues,

Itching is a very common symptom and a condition that worsens people's quality of life. Itching occurs in many cutaneous diseases. Moreover, it can also be triggered by various systemic diseases or external irritants. This Special Issue introduces experimental and clinical studies on the molecular, biological, and immunological mechanisms as well as the neurological mechanisms, involving both central and peripheral pathways, of itching. In addition, recent studies of new topical and systemic therapeutics based on the pathophysiology of itch will be presented.

Prof. Dr. Hye One Kim
Prof. Dr. Won-Sik Shim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pruritus
  • Itch
  • Pathophysiology of Itch
  • Pruritogen
  • Treatment of Itch
  • Ion Channel

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

8 pages, 1074 KiB  
Article
Oral Alitretinoin for Patients with Refractory Prurigo
by Bo Young Chung, Ji Young Um, Seok Young Kang, Min Je Jung, Jin Cheol Kim, In-Suk Kwak, Chun Wook Park and Hye One Kim
Medicina 2020, 56(11), 599; https://doi.org/10.3390/medicina56110599 - 9 Nov 2020
Cited by 2 | Viewed by 2686
Abstract
Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and [...] Read more.
Background: prurigo is a chronic skin disorder associated with a history of chronic pruritus. The pathogenesis of prurigo is largely unknown and the treatment of prurigo is unsatisfactory and challenging. Conventional systemic treatments may be beneficial; however, their possible side effects and possible transient efficacy is still a problem. We aimed to present the clinical course and effect of treatment with alitretinoin on patients with prurigo nodularis initially treated with conventional treatments like oral antihistamine, cyclosporine, and phototherapy. Methods: all the patients had prurigo nodularis refractory to conventional treatment. Their medical records included demographic features, past medical history, duration of disease, and treatment modalities; and the clinical courses of the patients were reviewed for this retrospective study. We evaluated patient pruritus and skin lesions for the duration. Results: we present reports involving 10 patients with refractory prurigo. All the patients in our cases were treated with oral alitretinoin after previous treatments and reported the improvement of skin lesions and pruritus within 2 weeks to 3 months. Conclusions: we suggest that oral alitretinoin may be an effective and well tolerated treatment option for patients with intractable prurigo. Further clinical studies are warranted to confirm the long-lasting efficacy and safety of alitretinoin for treating patients with prurigo. Full article
(This article belongs to the Special Issue Pathophysiology and New Treatment of Itch)
►▼ Show Figures

Figure 1

7 pages, 1310 KiB  
Article
Itching Caused by TRPV3 (Transient Receptor Potential Vanilloid-3) Activator Application to Skin of Burn Patients
by Hye One Kim, Kim Jin Cheol, Kong Yu Gyeong and Kwak In Suk
Medicina 2020, 56(11), 560; https://doi.org/10.3390/medicina56110560 - 25 Oct 2020
Cited by 10 | Viewed by 2475
Abstract
Background and objectives: Postburn pruritus is a common complication of scars in burn patients. In our previous study, we discovered increased expression of TRPV3, TRPV4, and TRPA1. Among them, TRPV3, in particular, is predominantly expressed in the epidermis of the tissue of pruritic [...] Read more.
Background and objectives: Postburn pruritus is a common complication of scars in burn patients. In our previous study, we discovered increased expression of TRPV3, TRPV4, and TRPA1. Among them, TRPV3, in particular, is predominantly expressed in the epidermis of the tissue of pruritic burn scars. We sought to evaluate the correlation between the expression of TRPV3 activators and itching after application of TRPV3 activator carvacrol over burn scars. Materials and Methods: Design: This was a double-blind clinical trial with non-randomized distribution. Setting: This study was performed in a hospital setting. Patients or participants: Patients with itching of burn scars (numerical rating scale (NRS), <3; n = 8; Group 1 and NRS, ≥3; n = 16, Group 2) and healthy volunteers (n = 18, Group 3) were included. Interventions: The investigational drug carvacrol (100%, 75%, and 50%) and control drug (10% ethanol) were applied over the scars using IQ Ultimate™ 1 × 1 cm chamber sheets. Main variables of interest: The presence of pruritus, erythema, edema, and other skin lesions was evaluated. The verbal NRS scores were also compared. Results: Carvacrol induced more itching in Group 2 than in Groups 1 and 3. In Group 2, 100%, 75%, and 50% carvacrol caused significantly more itching (NRS score, 5.18 ± 3.04, 5.18 ± 3.04, and 4.93 ± 2.96, respectively) than that in Group 1 (NRS score, 1.00 ± 1.80, 1.00 ± 1.80, and 1.00 ± 1.80, respectively) and Group 3 (NRS score, 2.38 ± 1.94, 1.27 ± 1.32, respectively). Conclusions: The TRPV3 activator carvacrol can cause itching if applied over burn scars. This study can help understand the mechanism and prognosis of post-burn itching and contribute to the development of its treatment. Full article
(This article belongs to the Special Issue Pathophysiology and New Treatment of Itch)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop